Ben Yong 4

What Happened
Ben Yong, a director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), received equity awards on May 19, 2026. The Form 4 reports a grant of 3,800 restricted stock units (RSUs) that will settle into common shares and a 12,300-unit derivative award; both show an acquisition price of $0.00 (standard for compensation grants). Footnotes specify the 3,800 RSUs vest 100% on the one-year anniversary of the grant. The filing also notes the 12,300 amount includes 8,600 previously unvested RSUs and that an option award made under the 2024 Equity Compensation Plan will vest 100% one year from grant.

Key Details

• Transaction date: May 19, 2026; Form 4 filed May 21, 2026 (filed timely).
• Reported grants: 3,800 RSUs (settle in common stock) @ $0.00; 12,300 derivative units @ $0.00.
• Vesting: 3,800 RSUs vest 100% one year after grant; footnotes indicate the derivative includes previously reported unvested RSUs and an option award that also vests 100% in one year.
• Shares owned after transaction: not specified in the filing.
• Transaction code: "A" (award/grant); derivative entry clarified by footnotes.
• No cash paid and no immediate sale or exercise reported.

Context
RSUs convert to shares when they vest; option/derivative awards likewise grant rights that vest over time. These are compensation grants common for directors and do not reflect an open-market purchase or sale by the insider. The filing was submitted within the usual two-business-day window, so there is no late-filing indication.